Topical skin treatments do not increase the radiation dose to the skin during radiotherapy and, therefore, can be used by individuals with cancer prior to radiation treatments, according to study results.
All news from Radiology/ Radiotherapy
Marine and salmon polar lipids (PLs) extracted by conventional extractions with non-food-grade solvents (CE-salmon-PLs) possess antithrombotic bioactivities against platelet-activating factor (PAF) and thrombin. Similar effects of food-grade-extracted (FGE) marine PLs have not yet been reported.
The search for a biomarker predicting response to immune checkpoint inhibitors (ICI) has been an ongoing race with no candidate sprinting across the finish line. So far, the most studied biomarkers have been the programmed cell death 1 receptor ligand (PD-L1) and tumor mutational burden (TMB), but both have shown varying degrees of success.
The American Society of Hematology (ASH) has developed new guidelines for the treatment of venous thromboembolism (VTE); the clinical practice guidelines were recently published in Blood Advances.
Checkpoint inhibitor therapy is a form of cancer treatment immunotherapy currently under research. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system.
The US Food and Drug Administration (FDA) has approved a new drug for the treatment of acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow.
The agency has granted approval for calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals), an asparagine-specific enzyme, to be used as part of a multi-agent chemotherapeutic regimen in pediatric and young adult patients (age 1 month to 21 years).
New research indicates that cancer survivors carry greater financial burdens related to medical debt payments and bills compared with individuals without a cancer history, with the greatest hardships in younger survivors.
A powerful new technique combines expansion microscopy with lattice light-sheet microscopy for nanoscale imaging of fly and mouse neuronal circuits and their molecular constituents that's roughly 1,000 times faster than other methods. Imaging the fly brain in multiple colors took just 62.5 hours, compared to the years it would take using an electron microscope, Boyden, Betzig, and their colleagues report in the journal, Science.
Researchers at Queen's University Belfast have developed a highly innovative new enzyme biomarker test that has the potential to indicate diseases and bacterial contamination saving time, money and possibly lives. The test, developed by scientists at the Institute for Global Food Security at Queen's, can detect enzyme markers of disease known as proteases in humans, animals and food products.
Dr Claire McVey, Queen's researcher and co-author on the study published in leading journal Nano Research, explains: "Not only is the test cheap to produce, but it can be used anywhere and is not reliant on laboratory conditions. Eliminating the need to carry out tests in a laboratory setting is life-changing. As well as being cost-effective, it means faster diagnosis."
Glycated hemoglobin A1c (HbA1c) is routinely used as a marker of average glycemic control, but it fails to provide data on hypoglycemia and glycemic variability, both of which are associated with adverse clinical outcomes.
Breast cancer will strike 1 in 8 women in her lifetime. But women who face an increased risk of being that one unlucky patient may improve their chances with three prescription medications, according to a new report. For women at average risk of breast cancer, the harms of the drugs clearly outweigh their benefits, the panel said.
The new recommendations expand the medication toolkit that can be used to ward off breast cancer. For the first time, the task force added a class of drugs called aromatase inhibitors to the cancer-prevention lineup. These drugs include anastrozole (known commercially as Arimidex), exemestane (Aromasin) and letrozole (Femara).